In a research collaboration with Mayo Clinic, nanomedical company NaNotics LLC plans to develop and assess a novel subtractive nanoparticle for use in cancer treatment.
The company’s nanoparticles, NaNots, treat disease by capturing and clearing pathogenic molecules from the blood. The goal of the current collaboration is to generate a NaNot that targets the soluble form of the PD-L1 protein, submit an investigational new drug application to the FDA and initiate human trials within 2 years.
“NaNots invert the normal drug paradigm — whereas drugs add molecules to the body,